Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

Yasuhito Arai, Yasushi Totoki, Fumie Hosoda, Tomoki Shirota, Natsuko Hama, Hiromi Nakamura, Hidenori Ojima, Koh Furuta, Kazuaki Shimada, Takuji Okusaka, Tomoo Kosuge, Tatsuhiro Shibata

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood. Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to improvements in the outcome of patients. We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212). The rearrangements were mutually exclusive with KRAS/BRAF mutations. Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of subcutaneous transplanted cells in immune-compromised mice. This transforming ability was attributable to its kinase activity. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Conclusion: FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma. The expression pattern of these fusions in association with sensitivity to FGFR inhibitors warrant a new molecular classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease.

Original languageEnglish
Pages (from-to)1427-1434
Number of pages8
JournalHepatology
Volume59
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 2
Cholangiocarcinoma
Protein-Tyrosine Kinases
Phosphotransferases
Fibroblast Growth Factor Receptors
Neoplasms
Gene Fusion
Therapeutics
Reverse Transcriptase Polymerase Chain Reaction
Oncogenes
Transcriptome
Stomach Neoplasms
Hepatocellular Carcinoma
Carcinogenesis
2-tyrosine
Mutation
Growth

ASJC Scopus subject areas

  • Hepatology

Cite this

Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., ... Shibata, T. (2014). Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology, 59(4), 1427-1434. https://doi.org/10.1002/hep.26890

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. / Arai, Yasuhito; Totoki, Yasushi; Hosoda, Fumie; Shirota, Tomoki; Hama, Natsuko; Nakamura, Hiromi; Ojima, Hidenori; Furuta, Koh; Shimada, Kazuaki; Okusaka, Takuji; Kosuge, Tomoo; Shibata, Tatsuhiro.

In: Hepatology, Vol. 59, No. 4, 2014, p. 1427-1434.

Research output: Contribution to journalArticle

Arai, Y, Totoki, Y, Hosoda, F, Shirota, T, Hama, N, Nakamura, H, Ojima, H, Furuta, K, Shimada, K, Okusaka, T, Kosuge, T & Shibata, T 2014, 'Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma', Hepatology, vol. 59, no. 4, pp. 1427-1434. https://doi.org/10.1002/hep.26890
Arai, Yasuhito ; Totoki, Yasushi ; Hosoda, Fumie ; Shirota, Tomoki ; Hama, Natsuko ; Nakamura, Hiromi ; Ojima, Hidenori ; Furuta, Koh ; Shimada, Kazuaki ; Okusaka, Takuji ; Kosuge, Tomoo ; Shibata, Tatsuhiro. / Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. In: Hepatology. 2014 ; Vol. 59, No. 4. pp. 1427-1434.
@article{53ff1c8102254d8e9acd36008352622e,
title = "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma",
abstract = "Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood. Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to improvements in the outcome of patients. We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6{\%}), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212). The rearrangements were mutually exclusive with KRAS/BRAF mutations. Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of subcutaneous transplanted cells in immune-compromised mice. This transforming ability was attributable to its kinase activity. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Conclusion: FGFR2 fusions occur in 13.6{\%} of intrahepatic cholangiocarcinoma. The expression pattern of these fusions in association with sensitivity to FGFR inhibitors warrant a new molecular classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease.",
author = "Yasuhito Arai and Yasushi Totoki and Fumie Hosoda and Tomoki Shirota and Natsuko Hama and Hiromi Nakamura and Hidenori Ojima and Koh Furuta and Kazuaki Shimada and Takuji Okusaka and Tomoo Kosuge and Tatsuhiro Shibata",
year = "2014",
doi = "10.1002/hep.26890",
language = "English",
volume = "59",
pages = "1427--1434",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

AU - Arai, Yasuhito

AU - Totoki, Yasushi

AU - Hosoda, Fumie

AU - Shirota, Tomoki

AU - Hama, Natsuko

AU - Nakamura, Hiromi

AU - Ojima, Hidenori

AU - Furuta, Koh

AU - Shimada, Kazuaki

AU - Okusaka, Takuji

AU - Kosuge, Tomoo

AU - Shibata, Tatsuhiro

PY - 2014

Y1 - 2014

N2 - Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood. Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to improvements in the outcome of patients. We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212). The rearrangements were mutually exclusive with KRAS/BRAF mutations. Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of subcutaneous transplanted cells in immune-compromised mice. This transforming ability was attributable to its kinase activity. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Conclusion: FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma. The expression pattern of these fusions in association with sensitivity to FGFR inhibitors warrant a new molecular classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease.

AB - Cholangiocarcinoma is an intractable cancer, with limited therapeutic options, in which the molecular mechanisms underlying tumor development remain poorly understood. Identification of a novel driver oncogene and applying it to targeted therapies for molecularly defined cancers might lead to improvements in the outcome of patients. We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212). The rearrangements were mutually exclusive with KRAS/BRAF mutations. Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of subcutaneous transplanted cells in immune-compromised mice. This transforming ability was attributable to its kinase activity. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Conclusion: FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma. The expression pattern of these fusions in association with sensitivity to FGFR inhibitors warrant a new molecular classification of cholangiocarcinoma and suggest a new therapeutic approach to the disease.

UR - http://www.scopus.com/inward/record.url?scp=84896492774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896492774&partnerID=8YFLogxK

U2 - 10.1002/hep.26890

DO - 10.1002/hep.26890

M3 - Article

C2 - 24122810

AN - SCOPUS:84896492774

VL - 59

SP - 1427

EP - 1434

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -